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LETTERS TO THE EDITOR
Some Questions Regarding
Myocardial Bridges Still Require Answers
Among the first groups to investigate such coronary anomalies, Dr.
Bourassa and collaborators in a recent review (1) attempted to
summarize current knowledge on the difficult subject of myocardial
bridges. I would like to discuss some notions that were suggested
by the investigators.
First, the concept of “symptomatic” muscular bridges (which the
review is said to be concerned with) is not defined and indeed is
quite unlikely to be definable, especially while reviewing the
literature. Such observation is fundamental when an investigator
attempts to establish anatomo-clinical correlations in a matter of
coronary anomalies. Indeed, one still cannot identify any consistent
clinical manifestations of muscular bridges (as expected to be
found, for example, in fixed severe coronary obstructions). What
literature reviews can do at their best is to establish correlations in
the specific cases that are being published. It is likely that some 2%
of the general population (possibly 120 million people in the
world) carry an angiographically recognizable muscular bridge, but
only few cases are symptomatic and/or have been published. No
large prospective series has yet been studied, and the problem of
the denominator (the number of people with similar anatomic
features of the few published) is the recurrent limit of clinical
studies of patients with coronary anomalies (2). Ideally, a large
population with anatomically similar anomalies and with similar
functional correlates should be entered into a large multicenter
database, using prospective, agreed-upon protocols that could
study the natural history of such patients (2).
Second, the recent availability of newer, more refined imaging
techniques (such as intravascular ultrasound) and use of functional
testing (Doppler or pressure wires and coronary reserve indexes)
have succeeded in improving the precision of new descriptive
parameters, but they have not yet resulted in proving a necessarily
ischemic implication of muscular bridges. In particular, the finding
of a mildly diminished coronary flow reserve (typically by Doppler
flow velocity measurements) does not explain resting nor severe
angina (that can be expected only with more limited reserve) nor
the probability to predict acute myocardial infarction or sudden
death, the typical clinical correlates in literature reports. Such
events are the real strong indicators for interventions. Doppler
findings of peculiar (typical) flow patterns are possibly diagnostic
of such anomalies, but they are not necessarily predictive per se of
clinical events.
Finally, although the problem of establishing firm, objective
criteria for indicating interventional treatment in muscular bridges
remains substantially unsolved, the decision on which intervention
should be contemplated as an alternative to medical treatment is
not so routine, as stated by the investigators (“these interventions
are not strikingly different from those of patients with single-vessel
coronary disease”). Indeed, both coronary stents and mammary
artery implantation were recognized to have important peculiarities
when implemented in such coronary anomalies. Stents have been
reported to lead to 46% restenosis rate at seven weeks’ angio-
graphic follow-up, in a series of 11 patients (3). Besides intimal
fibrocellular growth and clotting, crushing of a nonelastic metallic
stent is expected in the presence of muscular bridges-related
phasically active collapsing forces (4). Furthermore, mammary
artery implantation has been recognized to frequently undergo
atrophy when used in patients without significant baseline hemo-
dynamic gradients (5).
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REPLY
In his comments on our recent state-of-the-art study (1), Dr.
Angelini implies that our literature review on symptomatic myo-
cardial bridges failed to define the incidence, natural history, and
pathophysiology of this clinical entity. Although we also believe
that the study of the incidence and natural history of myocardial
bridges should be restricted to specific patient populations, namely
those with typical symptoms and objective signs of ischemia, we
agree that the follow-up of patients with any type of bridging has
not been helpful in the past (2,3). We do not share his view that,
overall, myocardial bridges are unlikely to produce ischemia (4).
Typical angina, exercise-induced ST-segment depression, positive
myocardial scintigraphy, and abnormal intracoronary Doppler flow
velocities are recognized manifestations of ischemia. The mecha-
nism of this ischemia has recently been clarified and consists of
significant diastolic coronary diameter reduction, in addition to
phasic systolic compression. We share Dr. Angelini’s concern
about the correct management of patients with symptomatic
bridges. As we have stated, medical therapy must be the first and
principal strategy, and interventions should be limited to patients
with refractory angina despite medical therapy. Then coronary
stenting and cardiac surgery, especially mammary artery implan-
tation, can achieve long-lasting relief of angina. We are not aware
of cases of crushing of a metallic stent in the presence of a muscular
bridge nor was this mentioned in the investigators’ previous report
(4). Finally, it is well known that mammary graft failure can occur
whenever anterograde flow is unimpaired, underscoring the im-
portance of careful patient selection.
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Mechanisms Behind
Intracoronary Radiation Therapy Failure
We read with great interest the study by Ajani et al., “The
Outcome of Percutaneous Coronary Intervention in Patients With
In-Stent Restenosis Who Failed Intracoronary Radiation Ther-
apy” (1). Limited data are available on the outcomes of patients
with in-stent restenosis (ISR) who undergo treatment using
intracoronary radiation therapy (IRT) and subsequently “fail,” and
the study by Ajani and colleagues provides new data on this
important subject. The investigators reported that the rate of failed
IRT was 29%. This is similar to findings from our institution
where we reported a 15.6% failure rate after IRT for ISR in a broad
range of patients (2). In our study, ostial location and smaller
postprocedural minimal luminal diameter were correlated with
subsequent failure after IRT. Do the investigators of this current
study have information regarding the effects of these factors on
influencing long-term clinical outcomes in their patient cohort?
In this current study, cutting balloon angioplasty (CBA) was
utilized in only 2% of cases after failed IRT. Because of the
potential for minimizing arterial injury, reducing the proliferative
neointimal response, achieving a greater postprocedural minimal
luminal diameter, and decreasing slippage due to “watermelon
seeding,” CBA has been shown to be a safe and feasible strategy for
the treatment of ISR (3); however, the impact of CBA in
combination with IRT for the treatment of ISR has not been well
established. We recently reported data from our institution which
showed that the strategy of CBA and IRT using Sr-90 for ISR was
associated with similar major adverse cardiac events (death, myo-
cardial infarction, and target vessel revascularization) at 6 months
compared to percutaneous transluminal coronary angioplasty
(PTCA) and IRT in 102 consecutive patients (20.0% vs. 29.8%,
p  0.36) (4). Thus, although CBA has the potential of avoiding
geographic miss by limiting the mismatch between the injured and
irradiated arterial segments, it does not appear to offer any clinical
advantage over conventional balloon angioplasty in combination
with IRT, although further studies are needed to clarify this issue.
The mechanism behind this observed lack of benefit for the
treatment of ISR may be that, although CBA appears to increase
neointimal tissue extrusion, intravascular ultrasound studies have
shown that CBA, unlike PTCA, is associated with minimal stent
overexpansion (5).
The majority of the patients in the current study presented with
a focal pattern of restenosis. Did the clinical presentation of these
patients differ from those who presented with diffuse or edge
restenosis?
In the study by Ajani et al. (1), the mean time to first target
vessel revascularization (TVR) was 173  127 days after the index
procedure. Other studies have noted that in patients who “fail”
IRT, treatment with brachytherapy delays the time to the first
TVR (295 206 days) compared to the placebo group (202 167
days) (p  0.03) (6). Preliminary data from our medical center
suggests that up to 25% of patients who ultimately “fail” IRT
present more than eight months after the index treatment, and in
these patients the mean duration to TVR was 14.2  3.7 months
(7). Do the investigators of the current study (1) have data on
patients who failed IRT and who presented beyond the traditional
time period for restenosis (six to nine months)?
Although glycoprotein IIb/IIIa inhibitors (GPI) have been
shown to be beneficial in a wide variety of coronary interventional
procedures, the impact of these agents on improving outcomes in
patients with ISR using IRT is not clearly defined. One study
showed that the utilization of GPI in conjunction with IRT for
ISR was associated with similar death, myocardial infarction, and
TVR compared to IRT without GPI (19.5% vs. 23.7%, p 0.511)
(8). What was the rate of utilization of GPI in the current study,
and did this influence the outcome?
The study by Ajani and co-workers contributes greatly to our
understanding of the issues surrounding the optimal implementa-
tion of IRT in this high-risk population. Assessing the risk for
IRT failure and elucidating the mechanisms underlying these
adverse events will contribute significantly to the application of
IRT for ISR in the drug-eluting stent era.
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